Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer

BACKGROUND: Approximately 25% of patients with early-stage breast cancer experience cancer progression throughout the disease course. Alterations in TMEM240 in breast cancer were identified and investigated to monitor treatment response and disease progression. METHODS: Circulating methylated TMEM24...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Ruo-Kai, Su, Chih-Ming, Lin, Shih-Yun, Thi Anh Thu, Le, Liew, Phui-Ly, Chen, Jian-Yu, Tzeng, Huey-En, Liu, Yun-Ru, Chang, Tzu-Hao, Lee, Cheng-Yang, Hung, Chin-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204905/
https://www.ncbi.nlm.nih.gov/pubmed/35715741
http://dx.doi.org/10.1186/s10020-022-00474-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204905/
https://www.ncbi.nlm.nih.gov/pubmed/35715741
http://dx.doi.org/10.1186/s10020-022-00474-9

Ejemplares similares